Skip to content

BIOTRICITY INC.: 10-Q filed 2023-11-14

What BIOTRICITY INC. reported in its quarterly report filed 2023-11-14 (fiscal Q2 2024): 44 published measures, 132 facts as tagged in accession 0001493152-23-041243.

This filing

Form
10-Q (quarterly report)
Filed
2023-11-14
Fiscal period
fiscal Q2 2024
Accession
0001493152-23-041243 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOTRICITY INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-09-306,823,837USD
At 2023-03-316,510,544USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-09-3032,295,289USD
At 2023-03-3126,355,929USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-09-30-26,729,036USD
At 2023-06-30-23,411,614USD
At 2023-03-31-19,845,385USD
At 2022-09-30-10,623,636USD
At 2022-06-30-6,560,418USD
At 2022-03-31-2,144,736USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-09-301,199,725USD
At 2023-03-31570,460USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,690,840USD92
2023-04-01 to 2023-09-30-7,103,722USD183
2022-07-01 to 2022-09-30-4,692,548USD92
2022-04-01 to 2022-09-30-9,468,800USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-04-01 to 2023-09-30-4,222,154USD183
2022-04-01 to 2022-09-30-8,490,203USD183

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-07-01 to 2023-09-302,891,297USD92
2023-04-01 to 2023-09-305,912,062USD183
2022-07-01 to 2022-09-302,381,389USD92
2022-04-01 to 2022-09-304,437,441USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-04-01 to 2023-09-304,758,634USD183
2022-04-01 to 2022-09-30-1,105,998USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-09-30-120,053,686USD
At 2023-03-31-112,570,825USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2023-09-308,795,742shares92
2023-04-01 to 2023-09-308,774,242shares183
2022-07-01 to 2022-09-308,642,937shares92
2022-04-01 to 2022-09-308,608,447shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-07-01 to 2023-09-308,795,742shares92
2023-04-01 to 2023-09-308,774,242shares183
2022-07-01 to 2022-09-308,642,937shares92
2022-04-01 to 2022-09-308,608,447shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.441USD/shares92
2023-04-01 to 2023-09-30-0.853USD/shares183
2022-07-01 to 2022-09-30-0.567USD/shares92
2022-04-01 to 2022-09-30-1.153USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.441USD/shares92
2023-04-01 to 2023-09-30-0.853USD/shares183
2022-07-01 to 2022-09-30-0.567USD/shares92
2022-04-01 to 2022-09-30-1.153USD/shares183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-09-3018,529USD
At 2023-03-3121,506USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-04-01 to 2023-09-30374,515USD183
2022-04-01 to 2022-09-30302,528USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-2,185,673USD92
2023-04-01 to 2023-09-30-4,502,159USD183
2022-07-01 to 2022-09-30-4,028,987USD92
2022-04-01 to 2022-09-30-8,117,648USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-09-305,178,206USD
At 2023-03-314,720,202USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-07-01 to 2023-09-30753,268USD92
2023-04-01 to 2023-09-301,413,780USD183
2022-07-01 to 2022-09-30403,551USD92
2022-04-01 to 2022-09-30791,940USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-09-3017,824,363USD
At 2023-03-3111,160,768USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-09-301,610,074USD
At 2023-03-311,224,137USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-07-01 to 2023-09-304,184,951USD92
2023-04-01 to 2023-09-308,418,141USD183
2022-07-01 to 2022-09-305,309,224USD92
2022-04-01 to 2022-09-3010,623,014USD183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-09-302,128,196USD
At 2023-03-312,337,006USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,999,278USD92
2023-04-01 to 2023-09-303,915,982USD183
2022-07-01 to 2022-09-301,280,237USD92
2022-04-01 to 2022-09-302,505,366USD183

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-07-01 to 2023-09-30892,019USD92
2023-04-01 to 2023-09-301,996,080USD183
2022-07-01 to 2022-09-301,101,152USD92
2022-04-01 to 2022-09-301,932,075USD183

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2023-07-01 to 2023-09-303,487,331USD92
2023-04-01 to 2023-09-307,007,546USD183
2022-07-01 to 2022-09-304,480,310USD92
2022-04-01 to 2022-09-308,972,924USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-30697,620USD92
2023-04-01 to 2023-09-301,410,595USD183
2022-07-01 to 2022-09-30828,914USD92
2022-04-01 to 2022-09-301,650,090USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-09-308,565,795shares
At 2023-03-318,508,052shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-09-3093,338,220USD
At 2023-03-3192,844,478USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-09-30-47,387USD
At 2023-03-31-152,797USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-09-301,409,172USD
At 2023-03-311,587,492USD
At 2022-09-301,140,209USD
At 2022-03-311,242,700USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-09-301,531,231USD
At 2023-03-311,722,095USD
At 2022-09-301,229,888USD
At 2022-03-311,330,338USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-09-3029,767USD
At 2023-03-3129,767USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-09-3011,238USD
At 2023-03-318,261USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-09-302,119,545USD
At 2023-03-311,607,353USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,690,840USD92
2023-04-01 to 2023-09-30-7,103,722USD183
2022-07-01 to 2022-09-30-4,692,548USD92
2022-04-01 to 2022-09-30-9,468,800USD183

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-04-01 to 2023-09-30-7,103,722USD183
2022-04-01 to 2022-09-30-9,468,800USD183

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,600,042USD92
2023-04-01 to 2023-09-30-7,377,451USD183
2022-07-01 to 2022-09-30-4,438,850USD92
2022-04-01 to 2022-09-30-9,230,235USD183

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,881,282USD92
2023-04-01 to 2023-09-30-7,482,861USD183
2022-07-01 to 2022-09-30-4,904,367USD92
2022-04-01 to 2022-09-30-9,928,756USD183

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,489USD92
2023-04-01 to 2023-09-302,977USD183
2022-07-01 to 2022-09-301,489USD92
2022-04-01 to 2022-09-302,977USD183

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-143,380USD92
2023-04-01 to 2023-09-30-129,945USD183
2022-07-01 to 2022-09-302,891USD92
2022-04-01 to 2022-09-302,891USD183

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-04-01 to 2023-09-301,046,621USD183
2022-04-01 to 2022-09-30620,714USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-04-01 to 2023-09-30119,285USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-09-01 to 2023-09-301,025,399USD30
2023-04-01 to 2023-09-30411,440USD183
2022-04-01 to 2022-09-3053,732USD183

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-09-30-208,810USD183
2022-04-01 to 2022-09-301,010,630USD183

Inspect the source

Entity
BIOTRICITY INC. / CIK 0001630113
Captured
SEC response SHA-256
de56e3354d4180362d8bf36a6dd02ff7fd0db9690bc31c81e452959deb9a8d37

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001630113.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))